naa a22 4500 510760112 CHVBK 20180411083136.0 cr unu---uuuuu 180411e20130201xx s 000 0 eng 10.1007/s11420-012-9307-7 doi (NATIONALLICENCE)springer-10.1007/s11420-012-9307-7 Development of Polymeric Nanocarrier System for Early Detection and Targeted Therapeutic Treatment of Peri-Implant Osteolysis [Elektronische Daten] [P. Purdue, Adam Levin, Ke Ren, Thomas Sculco, Dong Wang, Steven Goldring] Background: Extensive research has implicated inflammation as a necessary and causative factor in the development of peri-implant osteolysis, suggesting that such an inflammatory response is the sentinel event for the process. The potential to impact the clinical course of this condition is hampered by the lack of an effective medical therapy, as well as a limited ability for early detection prior to radiographically evident osteolysis. Advances in nanotechnology have allowed for the production of engineered water-soluble nanocarriers, which exploit changes in the microvascular architecture for selective distribution to inflamed tissues. Evaluation of the uptake of the nanocarriers in sites of inflammation has elucidated a novel mechanism of cellular uptake and retention of these particles. Purpose: The current review discusses the development of a novel, biocompatible, water-soluble nanocarrier utilizing copolymers of N-(2-hydroxypropyl)methacrylamide (HPMA), conjugated to imaging and therapeutic agents for the detection and targeted treatment of inflammatory conditions. Methods: We performed Medline searches for the terms "periprosthetic osteolysis,” "murine osteolysis model,” "HPMA osteolysis,” and "HPMA inflammation.” These searches identified 631, 306, 1, and 6 articles, respectively. These were then manually searched for articles relevant to the development of mouse models for inflammatory osteolysis and the use of HPMA copolymer technology in mouse models of inflammation. Results: Promising results in a small animal model of osteolysis have demonstrated the capability for detection prior to the development of bone loss, and have highlighted the utility of nanocarriers for selective drug delivery to the affected tissues. Conclusions: Challenges to the clinical translation of HPMA nanocarriers in peri-implant osteolysis remain, and the future research directions necessary for human clinical application are reviewed. Hospital for Special Surgery, 2012 periprosthetic osteolysis nationallicence nanocarrier nationallicence HPMA nationallicence optical imaging nationallicence Purdue P. Hospital for Special Surgery, 535 East 70th Street, 10021, New York, NY, USA aut Levin Adam Hospital for Special Surgery, 535 East 70th Street, 10021, New York, NY, USA aut Ren Ke Department of Pharmaceutical Sciences, University of Nebraska Medical Center, 68198, Omaha, NE, USA aut Sculco Thomas Hospital for Special Surgery, 535 East 70th Street, 10021, New York, NY, USA aut Wang Dong Department of Pharmaceutical Sciences, University of Nebraska Medical Center, 68198, Omaha, NE, USA aut Goldring Steven Hospital for Special Surgery, 535 East 70th Street, 10021, New York, NY, USA aut HSS Journal ® Springer-Verlag 9/1(2013-02-01), 79-85 1556-3316 9:1<79 2013 9 11420 https://doi.org/10.1007/s11420-012-9307-7 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s11420-012-9307-7 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Purdue P. Hospital for Special Surgery, 535 East 70th Street, 10021, New York, NY, USA aut NATIONALLICENCE 700 1- Levin Adam Hospital for Special Surgery, 535 East 70th Street, 10021, New York, NY, USA aut NATIONALLICENCE 700 1- Ren Ke Department of Pharmaceutical Sciences, University of Nebraska Medical Center, 68198, Omaha, NE, USA aut NATIONALLICENCE 700 1- Sculco Thomas Hospital for Special Surgery, 535 East 70th Street, 10021, New York, NY, USA aut NATIONALLICENCE 700 1- Wang Dong Department of Pharmaceutical Sciences, University of Nebraska Medical Center, 68198, Omaha, NE, USA aut NATIONALLICENCE 700 1- Goldring Steven Hospital for Special Surgery, 535 East 70th Street, 10021, New York, NY, USA aut NATIONALLICENCE 773 0- HSS Journal ® Springer-Verlag 9/1(2013-02-01), 79-85 1556-3316 9:1<79 2013 9 11420 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer